Drug Profile


Alternative Names: GSK 2696266; RSC 649266; S 649266

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shionogi
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gram-negative infections

Most Recent Events

  • 30 Jul 2017 Shionogi initiates enrolment in a phase III trial for Gram negative infections in USA (IV) (NCT03032380)
  • 01 Jun 2017 Antimicrobial data from in vitro studies in Gram negative infections presented at the American Society for Microbiology Microbe annual meeting (ASM-2017)
  • 22 Apr 2017 Antimicrobial data from preclinical trials in Gram-negative infections presented at the at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top